StockData
Evotec SE logo

Evotec SE (EVO) income statement

EVONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as EVOTF
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 8, 2026Score 4/30
$1.46−0.02 (-1.35%)

Close on Nov 18, 2026Market cap $519.11MP/E –Yield –

Evotec SE income statement

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY2025

Gross margin
14.5%
Operating margin
-7.1%
Net margin
–
Return on equity, FY2025
–

Financial strength

Current ratio
2.07
Debt to equity
–
Debt to assets
–
Cash to current liabilities
113.7%

Valuation

P/E ratio
–
Price to sales
0.60
Price to book
0.58
Dividend yield
–

See a number that looks wrong?